Merck & Company Company Profile (NYSE:MRK)

About Merck & Company

Merck & Company logoMerck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Company's animal health products are sold to veterinarians, distributors and animal producers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: MRK
  • CUSIP: 58933Y10
Key Metrics:
  • Previous Close: $66.16
  • 50 Day Moving Average: $63.09
  • 200 Day Moving Average: $62.14
  • 52-Week Range: $2,757,137,000.00 - $50.09
  • Trailing P/E Ratio: 32.43
  • Foreward P/E Ratio: 15.75
  • P/E Growth: 2.61
  • Market Cap: $182.41B
  • Outstanding Shares: 2,757,137,000
  • Beta: 0.79
  • Net Margins: 14.30%
  • Return on Equity: 24.08%
  • Return on Assets: 10.77%
  • Debt-to-Equity Ratio: 0.54%
  • Current Ratio: 1.89%
  • Quick Ratio: 1.56%
Additional Links:
Companies Related to Merck & Company:

Analyst Ratings

Consensus Ratings for Merck & Company (NYSE:MRK) (?)
Ratings Breakdown: 1 Sell Rating, 6 Hold Ratings, 11 Buy Ratings
Consensus Rating:Buy (Score: 2.56)
Consensus Price Target: $67.40 (1.87% upside)

Analysts' Ratings History for Merck & Company (NYSE:MRK)
DateFirmActionRatingPrice TargetDetails
2/24/2017Sanford C. BernsteinReiterated RatingMarket PerformView Rating Details
2/15/2017BMO Capital MarketsLower Price TargetOutperform$72.00 -> $70.00View Rating Details
1/13/2017Bryan, Garnier & CoInitiated CoverageBuyView Rating Details
1/12/2017Jefferies Group LLCReiterated RatingUnderperform$48.00View Rating Details
1/12/2017Piper Jaffray CompaniesUpgradeNeutral -> Overweight$72.00View Rating Details
1/12/2017Morgan StanleyUpgradeEqual Weight -> Overweight$65.00 -> $71.00View Rating Details
1/12/2017GuggenheimUpgradeNeutral -> Buy$61.63 -> $70.00View Rating Details
1/11/2017J P Morgan Chase & CoReiterated RatingBuyView Rating Details
10/27/2016ArgusReiterated RatingBuy$65.00 -> $80.00View Rating Details
10/13/2016Bank of America CorpUpgradeNeutral -> Buy$57.00 -> $70.00View Rating Details
10/12/2016Leerink SwannReiterated RatingMarket Perform$65.00View Rating Details
10/12/2016Barclays PLCReiterated RatingOverweightView Rating Details
9/11/2016Berenberg BankReiterated RatingHold$62.00View Rating Details
8/10/2016Citigroup Inc.Reiterated RatingNeutral$65.00View Rating Details
8/8/2016Deutsche Bank AGBoost Price TargetHold$58.00 -> $59.00View Rating Details
8/7/2016Credit Suisse GroupUpgradeNeutral -> Outperform$62.00 -> $73.00View Rating Details
6/8/2016Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$60.00View Rating Details
4/6/2016Societe GeneraleInitiated CoverageBuyView Rating Details
2/5/2016S&P Equity ResearchReiterated RatingHold$56.00View Rating Details
2/3/2016Cowen and CompanyReiterated RatingHoldView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutralView Rating Details
(Data available from 2/27/2015 forward)


Earnings History for Merck & Company (NYSE:MRK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/2/2017Q416$0.89$0.89$10.22 billion$10.10 billionViewListenView Earnings Details
10/25/2016Q316$0.99$1.07$10.17 billion$10.50 billionViewListenView Earnings Details
7/29/2016Q216$0.91$0.93$9.79 billion$9.84 billionViewListenView Earnings Details
5/5/2016Q116$0.85$0.89$9.45 billion$9.30 billionViewN/AView Earnings Details
2/3/2016Q415$0.91$0.93$10.32 billion$10.22 billionViewListenView Earnings Details
10/27/2015Q315$0.91$0.96$10.11 billion$10.10 billionViewListenView Earnings Details
7/28/2015Q215$0.80$0.86$9.81 billion$9.80 billionViewListenView Earnings Details
4/28/2015Q115$0.75$0.85$9.04 billion$9.40 billionViewListenView Earnings Details
2/4/2015Q414$0.86$0.87$10.61 billion$10.48 billionViewListenView Earnings Details
10/27/2014Q314$0.88$0.90$10.66 billion$10.56 billionViewListenView Earnings Details
7/29/2014Q214$0.80$0.85$10.60 billion$10.93 billionViewListenView Earnings Details
4/29/2014Q114$0.79$0.88$10.44 billion$10.30 billionViewListenView Earnings Details
2/5/2014Q413$0.88$0.88$11.39 billion$11.30 billionViewListenView Earnings Details
10/28/2013Q313$0.88$0.92$11.19 billion$11.03 billionViewListenView Earnings Details
7/30/2013Q2 2013$0.82$0.84$11.22 billion$11.01 billionViewListenView Earnings Details
5/1/2013Q1 2013$0.79$0.85$11.09 million$10.70 millionViewListenView Earnings Details
2/1/2013Q4 2012$0.81$0.83$11.46 billion$11.70 billionViewListenView Earnings Details
10/26/2012Q312$0.92$0.95$11.60 billion$11.50 billionViewN/AView Earnings Details
7/27/2012$1.02$1.05ViewN/AView Earnings Details
4/27/2012$0.98$0.99ViewN/AView Earnings Details
2/2/2012$0.95$0.97ViewN/AView Earnings Details
10/28/2011$0.91$0.94ViewN/AView Earnings Details
7/29/2011$0.94$0.95ViewN/AView Earnings Details
4/29/2011$0.84$0.92ViewN/AView Earnings Details
2/3/2011$0.83$0.88ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Merck & Company (NYSE:MRK)
Current Year EPS Consensus Estimate: $3.82 EPS
Next Year EPS Consensus Estimate: $4.20 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$0.82$0.87$0.84
Q2 20163$0.92$0.92$0.92
Q3 20163$0.97$0.99$0.98
Q4 20163$0.89$0.93$0.90
Q1 20171$0.91$0.91$0.91
Q2 20171$0.93$0.93$0.93
Q3 20171$1.00$1.00$1.00
Q4 20171$1.02$1.02$1.02
(Data provided by Zacks Investment Research)


Current Dividend Information for Merck & Company (NYSE:MRK)
Annual Dividend:$1.88
Dividend Yield:2.84%
Dividend Growth:2.30% (3 Year Average)
Payout Ratio:92.61% (Based on Trailing 12 Months of Earnings)
49.21% (Based on Current Year Consensus EPS Estimate)
44.76% (Based on Next Year Consensus EPS Estimate)
Track Record:5 Years of Consecutive Dividend Growth

Dividend History for Merck & Company (NYSE:MRK)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Merck & Company (NYSE:MRK)
Insider Ownership Percentage: 0.05%
Institutional Ownership Percentage: 74.10%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/8/2017Patricia F RussoDirectorSell5,000$64.42$322,100.00View SEC Filing  
2/6/2017Wendell P WeeksDirectorSell5,000$64.51$322,550.00View SEC Filing  
2/3/2017Michael J HolstonEVPSell91,959$63.96$5,881,697.64View SEC Filing  
2/3/2017Thomas R CechDirectorSell5,000$63.42$317,100.00View SEC Filing  
11/10/2016Kenneth C FrazierChairmanSell140,000$65.03$9,104,200.00View SEC Filing  
11/7/2016Julie L GerberdingEVPSell85,523$60.02$5,133,090.46View SEC Filing  
11/2/2016Rochelle B LazarusDirectorSell20,000$59.06$1,181,200.00View SEC Filing  
10/3/2016Weir Mirian M GraddickInsiderSell40,800$62.07$2,532,456.00View SEC Filing  
9/1/2016Adam H SchechterEVPSell39,200$62.61$2,454,312.00View SEC Filing  
8/10/2016Clark GolestaniEVPSell3,000$63.03$189,090.00View SEC Filing  
8/5/2016Kenneth C FrazierChairmanSell392,000$61.81$24,229,520.00View SEC Filing  
7/5/2016Kenneth C FrazierCEOSell60,000$58.00$3,480,000.00View SEC Filing  
7/5/2016Weir Mirian M GraddickInsiderSell45,000$57.99$2,609,550.00View SEC Filing  
7/1/2016Adam H SchechterEVPSell50,000$57.69$2,884,500.00View SEC Filing  
7/1/2016Weir Mirian M GraddickInsiderSell30,000$57.49$1,724,700.00View SEC Filing  
5/20/2016Clark GolestaniEVPSell39,877$54.79$2,184,860.83View SEC Filing  
4/14/2016Kenneth C FrazierCEOSell131,040$56.11$7,352,654.40View SEC Filing  
11/4/2015Wendell P. WeeksDirectorSell5,000$55.53$277,650.00View SEC Filing  
10/29/2015Adele D. AmbroseinsiderSell37,313$55.08$2,055,200.04View SEC Filing  
10/29/2015Kenneth C. FrazierCEOSell18,666$54.69$1,020,843.54View SEC Filing  
10/28/2015Peter C. WendellDirectorSell5,000$54.85$274,250.00View SEC Filing  
5/11/2015Adam H SchechterEVPSell10,634$60.44$642,718.96View SEC Filing  
5/8/2015Julie L GerberdingEVPSell38,368$60.99$2,340,064.32View SEC Filing  
5/4/2015Bruce N KuhlikInsiderSell56,064$60.20$3,375,052.80View SEC Filing  
4/29/2015Bruce N KuhlikInsiderSell156,902$59.82$9,385,877.64View SEC Filing  
4/29/2015Michael J HolstonEVPSell95,624$59.84$5,722,140.16View SEC Filing  
2/18/2015Kenneth C FrazierCEOSell5,164$58.67$302,971.88View SEC Filing  
2/11/2015Willie A DeeseInsiderSell135,864$58.56$7,956,195.84View SEC Filing  
2/9/2015Peter C WendellDirectorSell5,000$58.76$293,800.00View SEC Filing  
1/15/2015Adam H SchechterEVPSell74,200$62.48$4,636,016.00View SEC Filing  
1/9/2015Kenneth C FrazierCEOSell8,840$62.47$552,234.80View SEC Filing  
12/10/2014Kenneth C FrazierCEOSell9,846$60.00$590,760.00View SEC Filing  
12/8/2014Bruce N KuhlikInsiderSell50,000$62.00$3,100,000.00View SEC Filing  
11/26/2014Rochelle B LazarusDirectorSell10,000$59.63$596,300.00View SEC Filing  
11/24/2014Wendell P WeeksDirectorSell5,000$59.13$295,650.00View SEC Filing  
11/10/2014Kenneth C FrazierCEOSell10,000$57.98$579,800.00View SEC Filing  
10/10/2014Kenneth C FrazierCEOSell9,895$59.73$591,028.35View SEC Filing  
9/10/2014Kenneth C FrazierCEOSell9,814$60.48$593,550.72View SEC Filing  
8/25/2014Adam H SchechterEVPSell22,000$59.70$1,313,400.00View SEC Filing  
8/11/2014Kenneth C FrazierCEOSell10,058$57.00$573,306.00View SEC Filing  
8/4/2014Adele D AmbroseInsiderSell28,669$56.64$1,623,812.16View SEC Filing  
7/10/2014Kenneth C FrazierCEOSell9,987$58.03$579,545.61View SEC Filing  
7/7/2014Weir Mirian M GraddickInsiderSell180,047$59.16$10,651,580.52View SEC Filing  
6/27/2014Willie A DeeseInsiderSell72,290$58.26$4,211,615.40View SEC Filing  
6/10/2014Kenneth C FrazierCEOSell9,985$58.06$579,729.10View SEC Filing  
5/14/2014Adam SchechterEVPSell10,527$55.91$588,564.57View SEC Filing  
4/10/2014Kenneth FrazierCEOSell10,047$57.24$575,090.28View SEC Filing  
4/4/2014Bruce KuhlikInsiderSell145,225$56.43$8,195,046.75View SEC Filing  
2/14/2014Clark GolestaniEVPSell5,990$55.47$332,265.30View SEC Filing  
2/13/2014Bridgette HellerVPSell43,870$55.04$2,414,604.80View SEC Filing  
2/11/2014Adam SchechterEVPSell18,000$55.61$1,000,980.00View SEC Filing  
2/11/2014John CananInsiderSell10,000$55.70$557,000.00View SEC Filing  
2/11/2014Kenneth FrazierCEOSell41,520$54.52$2,263,670.40View SEC Filing  
2/10/2014Peter WendellDirectorSell5,000$54.44$272,200.00View SEC Filing  
2/10/2014Willie DeeseInsiderSell50,000$54.68$2,734,000.00View SEC Filing  
8/7/2013Willie DeeseInsiderSell50,638$48.55$2,458,474.90View SEC Filing  
5/15/2013Adele D AmbroseInsiderSell34,208$46.66$1,596,145.28View SEC Filing  
5/13/2013Bridgette P HellerVPSell5,404$46.15$249,394.60View SEC Filing  
8/9/2012Willie A DeeseInsiderSell62,324$44.26$2,758,460.24View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Merck & Company (NYSE:MRK)
DateHeadline logoMerck’s Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in Bone Marrow Transplant Recipients, Highly Effective Through Week 24 Post-Transplant in Pivotal Phase 3 Study (NYSE:MRK) - February 26 at 5:46 PM logo12:43 pm Merck announces results of the pivotal Phase 3 clinical study of letermovir; study met its primary efficacy endpoint (NYSE:MRK) - February 26 at 5:46 PM logoMerck Antiviral Drug Reports Positive Data (MRK) - Investopedia (NYSE:MRK) - February 26 at 7:46 AM
News IconAnalyst's Indicator Review for Merck & Co., Inc. (MRK), CenturyLink, Inc. (CTL) - The USA Commerce (NYSE:MRK) - February 24 at 4:01 PM logoWall Street Analysts’ Estimates for Merck & Co. (NYSE:MRK) - February 24 at 4:01 PM logoEli Lilly & Co.’s Cardiovascular Franchise (NYSE:MRK) - February 24 at 4:01 PM logoMerck Antiviral Drug Reports Positive Data (NYSE:MRK) - February 24 at 4:01 PM logoIn First Phase 3 Trial, Merck’s Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64 Percent in Immunocompromised Subjects (NYSE:MRK) - February 24 at 4:01 PM
News IconMerck & Co., Inc.'s (MRK) Potential Shot in the Arm Could be Painful for Pfizer Inc.'s (PFE) Prevnar - Smаrt Stоck Nеws (NYSE:MRK) - February 24 at 9:19 AM
News IconMerck & Co., Inc. (MRK): An Examination Of The Chart For Today's Session - NY Stock News (NYSE:MRK) - February 24 at 9:19 AM logoMerck & Co., Inc. (NYSE:MRK) Files An 8-K Material Impairments - Market Exclusive (NYSE:MRK) - February 24 at 9:19 AM logoMerck Receives Positive CHMP Opinion for New Pergoveris® Fertility Pen (NYSE:MRK) - February 24 at 9:19 AM logoOnly 1 of 30 Dow stocks is trading higher premarket (NYSE:MRK) - February 24 at 9:19 AM logoMerck & Co.’s Profit Margins for 4Q16 (NYSE:MRK) - February 24 at 9:19 AM logoMerck : Reports Outline Clostridium difficile Study Results from Merck & Company (Development of a Novel Vaccine Containing Binary Toxin for the... (NYSE:MRK) - February 23 at 11:43 PM logoMerck (MRK) to Take $2.9B Pre-Tax Impairment Charge on HCV Drug (NYSE:MRK) - February 23 at 11:43 PM logoRemicade: Driving Down Merck & Co.’s Immunology Franchise (NYSE:MRK) - February 23 at 6:42 PM logoMerck drug prevents serious infection after marrow transplant -study (NYSE:MRK) - February 23 at 6:42 PM logoMERCK & CO., INC. Files SEC form 8-K, Material Impairments (NYSE:MRK) - February 23 at 6:42 PM logoMerck to take $2.9 billion charge on hepatitis C drug (NYSE:MRK) - February 23 at 6:42 PM
News IconAnalysts Are Circling Merck & Company, Inc. (NYSE:MRK): Where Do Research Brokers See It Going? - Winfield Review (NYSE:MRK) - February 23 at 8:13 AM
News IconAnalysts Near-Term outlook: Mylan NV (MYL), Merck & Co., Inc. (MRK) - The USA Commerce (NYSE:MRK) - February 23 at 8:13 AM
News IconForward Earnings Estimate of Merck & Company, Inc.(MRK) - Highland Mirror (NYSE:MRK) - February 23 at 8:13 AM
News IconWhy Do Stocks' Fair Value Estimates Change? (NYSE:MRK) - February 23 at 8:13 AM logoGardasil Driving Merck & Co.’s Vaccines Business in 4Q16 (NYSE:MRK) - February 23 at 8:13 AM
News IconMerck KGaA (MRK) PT Set at €110.00 by Warburg Research (NYSE:MRK) - February 22 at 11:47 PM
News IconMerck KGaA (MRK) Given a €103.00 Price Target by Morgan Stanley Analysts (NYSE:MRK) - February 22 at 11:47 PM logoMerck, Wal-Mart, Restaurant Brands International Upgraded (NYSE:MRK) - February 22 at 6:46 PM
News IconBrokerages Set Merck KGaA (MRK) Price Target at $104.74 (NYSE:MRK) - February 22 at 6:46 PM logoMerck & Co. Reported Flat Operational Revenues in 4Q16 (NYSE:MRK) - February 22 at 6:46 PM logoGilead Sciences Expects to See a Revenue Fall in 2017 (NYSE:MRK) - February 22 at 6:46 PM logoHouse Border Tax Plan Could Make Travel Abroad Cheaper for Americans (NYSE:MRK) - February 22 at 6:46 PM logoBristol Myers' Future Unsure as Carl Icahn Takes Stake (NYSE:MRK) - February 22 at 6:46 PM
News IconWhy Investors remained confident on Merck & Co., Inc. (MRK), VF Corporation (VFC)? - StockNewsJournal (NYSE:MRK) - February 22 at 8:33 AM
News IconTechnicals in Focus for Merck & Co., Inc. (MRK) - The USA Commerce (NYSE:MRK) - February 22 at 8:33 AM logoBristol-Myers, Merck, And Other Pharmaceutical Firms All Targeting ... - Market Exclusive (NYSE:MRK) - February 22 at 8:33 AM logoMerck and Co. Reports Flat Operational Revenues in 4Q16 (NYSE:MRK) - February 22 at 8:33 AM logoIcahn buys Bristol-Myers shares, adding to activist pressure (NYSE:MRK) - February 21 at 6:16 PM logoThese Six Dow Components Back Border Tax, But Shallow Support Shows Why It's In Trouble (NYSE:MRK) - February 21 at 6:16 PM logo[$$] Alzheimer's: Pharma's Great White Whale Is Still Worth Hunting (NYSE:MRK) - February 20 at 10:03 AM
News IconChecking Out the Technicals for Merck & Co., Inc. (MRK) - The USA Commerce (NYSE:MRK) - February 17 at 4:27 PM
News IconTaking a Fresh Look at Merck & Co., Inc. (MRK) - StockNewsJournal (NYSE:MRK) - February 17 at 4:27 PM logoMerck, Bristol-Myers, Incyte Race For A Cure In $25 Billion I-O Market (NYSE:MRK) - February 17 at 4:27 PM
News IconMerck & Company, Inc. (MRK) Shares Bought by Quantitative Systematic Strategies LLC (NYSE:MRK) - February 16 at 6:15 PM logoFossil and AIG slump, Procter & Gamble and Fortress jump (NYSE:MRK) - February 16 at 6:15 PM logoMerck’s Fight Against Infectious Disease Goes Digital with Launch of ILÚM Health Solutions (NYSE:MRK) - February 16 at 6:15 PM logoMerck HIV Drug Doravirine Reports Positive Results (NYSE:MRK) - February 16 at 6:15 PM logoAfter-hours buzz: ANET, TRUE, MRK & more (NYSE:MRK) - February 16 at 6:15 PM
News IconPharma giant Merck is stopping a key Alzheimer's trial because there's 'virtually no chance of finding a positive clinical effect' (NYSE:MRK) - February 15 at 1:15 AM
News IconMerck & Co., Inc. (MRK), Bristol-Myers Squibb Company (BMY) (NYSE:MRK) - February 15 at 1:15 AM


What is Merck & Company's stock symbol?

Merck & Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

How often does Merck & Company pay dividends? What is the dividend yield for Merck & Company?

Merck & Company declared a quarterly dividend on Tuesday, November 22nd. Shareholders of record on Thursday, December 15th will be given a dividend of $0.47 per share on Monday, January 9th. This represents a $1.88 annualized dividend and a dividend yield of 2.84%. The ex-dividend date of this dividend is Tuesday, December 13th. This is a boost from Merck & Company's previous quarterly dividend of $0.46.

Where is Merck & Company's stock going? Where will Merck & Company's stock price be in 2017?

18 analysts have issued 1 year price objectives for Merck & Company's shares. Their predictions range from $48.00 to $80.00. On average, they anticipate Merck & Company's stock price to reach $67.40 in the next twelve months.

When will Merck & Company announce their earnings?

Merck & Company is scheduled to release their next quarterly earnings announcement on Tuesday, May, 2nd 2017.

What are analysts saying about Merck & Company stock?

Here are some recent quotes from research analysts about Merck & Company stock:

  • BMO Capital Markets analysts commented, "Although expectations for EPOCH were low, we were looking for an efficacy signal in mild patients, which would have increased expectations for the APECS study. Merck's press release does not provide details regarding subgroup analysis in mild patients; however, the language suggests little to no efficacy. This lowers our probability of success for APECS from 50% to 25%, Verubecestat risk-adjusted sales from ~$5Bn in 2026 to ~$2.5Bn, and our valuation from $72 to $70. However, investors should not give up on Verubecestat; APECS has a higher chance of success." (2/15/2017)
  • Jefferies Group LLC analysts commented, "Our Underperform rating is predicated on under-appreciated margin pressure in the base business as well as over-optimistic expectations for Keytruda." (1/12/2017)

  • According to Zacks Investment Research, "We are positive on the company’s efforts to expand its pipeline and focus on core areas of expertise. Merck has made significant progress with its pipeline and is working on bringing new products to the market. New products, especially Keytruda should contribute meaningfully to the top line. The latest FDA approval of Keytruda for the first line treatment of metastatic lung cancer should sharply improve the drug’s sales. Merck will continue to focus on cost-cutting initiatives to drive the bottom line. The company has also been pursuing acquisitions and business development deals to boost its pipeline. Merck’s shares surpassed that of large-cap pharma industry this year. However, increased competition as well as generic challenges will continue to pressurize the top line. Nasonex and Cubicin lost patent exclusivity in 2016 which is hurting sales." (12/7/2016)

Who owns Merck & Company stock?

Merck & Company's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (1.04%), Barrow Hanley Mewhinney & Strauss LLC (0.64%), FMR LLC (0.49%), Federated Investors Inc. PA (0.41%), Dimensional Fund Advisors LP (0.24%) and AQR Capital Management LLC (0.24%). Company insiders that own Merck & Company stock include Adam H Schechter, Adele D Ambrose, Bruce N Kuhlik, Clark Golestani, Julie L Gerberding, Kenneth C Frazier, Michael J Holston, Patricia F Russo, Peter C Wendell, Rochelle B Lazarus, Thomas R Cech, Weir Mirian M Graddick and Wendell P Weeks.

Who sold Merck & Company stock? Who is selling Merck & Company stock?

Merck & Company's stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Highland Capital Management LP, Barrow Hanley Mewhinney & Strauss LLC, Tudor Investment Corp Et Al, NN Investment Partners Holdings N.V., Thornburg Investment Management Inc., Menora Mivtachim Holdings LTD. and I.G. Investment Management LTD.. Company insiders that have sold Merck & Company stock in the last year include Adam H Schechter, Clark Golestani, Julie L Gerberding, Kenneth C Frazier, Michael J Holston, Patricia F Russo, Rochelle B Lazarus, Thomas R Cech, Weir Mirian M Graddick and Wendell P Weeks.

Who bought Merck & Company stock? Who is buying Merck & Company stock?

Merck & Company's stock was purchased by a variety of institutional investors in the last quarter, including Asset Management One Co. Ltd., DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main, Russell Investments Group Ltd., AQR Capital Management LLC, Coho Partners Ltd., Congress Asset Management Co. MA, Radnor Capital Management LLC and Orbimed Advisors LLC.

How do I buy Merck & Company stock?

Shares of Merck & Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Merck & Company stock cost?

One share of Merck & Company stock can currently be purchased for approximately $66.16.

Merck & Company (NYSE:MRK) Chart for Monday, February, 27, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Merck & Company (NYSE:MRK)

Earnings History Chart

Earnings by Quarter for Merck & Company (NYSE:MRK)

Dividend History Chart

Dividend Payments by Quarter for Merck & Company (NYSE:MRK)

Last Updated on 2/27/2017 by Staff